BGI Genomics Co Ltd
SZSE:300676
Intrinsic Value
BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. [ Read More ]
The intrinsic value of one
BGI Genomics Co Ltd
stock under the Base Case scenario is
17.26
CNY.
Compared to the current market price of 39.74 CNY,
BGI Genomics Co Ltd
is
Overvalued by 57%.
BGI Genomics Co Ltd's market capitalization is 16.3B CNY.
BGI Genomics Co Ltd stock price is 39.74 CNY.
BGI Genomics Co Ltd stock (17.26 CNY) is 57% less than its price (39.74 CNY).
BGI Genomics Co Ltd stock (6.26 CNY) is 84% less than its price (39.74 CNY). Open DCF Valuation
BGI Genomics Co Ltd stock (28.27 CNY) is 29% less than its price (39.74 CNY). Open Relative Valuation
BGI Genomics Co Ltd has upside potential of 154% compared to the average analyst price target.
Open Wall St Estimates
BGI Genomics Co Ltd has positive Net Income for the last twelve months.
BGI Genomics Co Ltd has positive Operating Income for the last twelve months.
BGI Genomics Co Ltd has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
BGI Genomics Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
BGI Genomics Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 1%.
BGI Genomics Co Ltd has positive three-year average ROIC (Return on Invested Capital): 18%. The company is efficient at using invested capital to generate operating income.
BGI Genomics Co Ltd has negative Free Cash Flow for the last twelve months.
BGI Genomics Co Ltd's Revenue has dropped by 38% over the past 12 months.
BGI Genomics Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 38% to 1%.
BGI Genomics Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 52% to 1%.
BGI Genomics Co Ltd's short-term assets (8B CNY) exceed its short-term liabilties (3B CNY).
BGI Genomics Co Ltd's Revenue has been falling by 20% per year for the last 3 years.
BGI Genomics Co Ltd has positive Gross Profit for the last twelve months.
BGI Genomics Co Ltd's Altman Z-Score is very high and is equal to 3.92.
BGI Genomics Co Ltd's long-term assets (14B CNY) exceed its long-term liabilties (4B CNY).
BGI Genomics Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.03.
BGI Genomics Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (5B CNY) than debt (299m CNY).
Valuation Backtest
BGI Genomics Co Ltd
Run backtest to discover the historical profit from buying and selling
BGI Genomics Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
BGI Genomics Co Ltd
Balance Sheet Decomposition
BGI Genomics Co Ltd
| Current Assets | 7.9B |
| Cash & Short-Term Investments | 5.4B |
| Receivables | 1.6B |
| Other Current Assets | 852.5m |
| Non-Current Assets | 5.7B |
| Long-Term Investments | 1.3B |
| PP&E | 3.2B |
| Intangibles | 627m |
| Other Non-Current Assets | 574.6m |
| Current Liabilities | 3.3B |
| Accounts Payable | 850.2m |
| Accrued Liabilities | 350m |
| Short-Term Debt | 15.9m |
| Other Current Liabilities | 2.1B |
| Non-Current Liabilities | 456.7m |
| Long-Term Debt | 283.4m |
| Other Non-Current Liabilities | 173.3m |
Earnings Waterfall
BGI Genomics Co Ltd
|
Revenue
|
4.3B
CNY
|
|
Cost of Revenue
|
-2.2B
CNY
|
|
Gross Profit
|
2.2B
CNY
|
|
Operating Expenses
|
-2B
CNY
|
|
Operating Income
|
126.9m
CNY
|
|
Other Expenses
|
-34m
CNY
|
|
Net Income
|
92.9m
CNY
|
Free Cash Flow Analysis
BGI Genomics Co Ltd
Profitability Score
Profitability Due Diligence
BGI Genomics Co Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
BGI Genomics Co Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
BGI Genomics Co Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
BGI Genomics Co Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
BGI Genomics Co Ltd
According to Wall Street analysts, the average 1-year price target for
BGI Genomics Co Ltd
is 100.77 CNY
.
Shareholder Return
Price
BGI Genomics Co Ltd
| Average Annual Return | 4.91% |
| Standard Deviation of Annual Returns | 57.61% |
| Max Drawdown | -81% |
| Market Capitalization | 16.3B CNY |
| Shares Outstanding | 409 913 859 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
BGI Genomics Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. The company is headquartered in Shenzhen, Guangdong and currently employs 4,333 full-time employees. The company went IPO on 2017-07-14. The firm's main products and services include reproductive health basic research and clinical application services, basic science research services (genome sequencing, bioinformatics analysis and other multithreaded solutions), complex disease basic research and clinical application services, as well as drugs basic research and clinical application services. The firm mainly provides services for domestic and overseas academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals and medical institutions, among others. The firm mainly operates its businesses in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
BGI Genomics Co Ltd
stock under the Base Case scenario is
17.26
CNY.
Compared to the current market price of 39.74 CNY,
BGI Genomics Co Ltd
is
Overvalued by 57%.
You don't have any saved screeners yet
